Vivos Therapeutics, Inc. (VVOS): Cost of Revenue
$6.90M
Year ended 2025-12-31
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.90M | +14.8% | 2026-04-15, From 2025-01-01 |
| 2024-12-31 | $6.01M | +8.7% | 2026-04-15, From 2024-01-01 |
| 2023-12-31 | $5.53M | n/a | 2025-03-31, From 2023-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Vivos Therapeutics, Inc. (VVOS) | 2025-12-31 | $6.90M | +14.8% |
| Nephros Inc (NEPH) | 2025-12-31 | $7.16M | +31.7% |
| Profound Medical Corp. (PROF) | 2025-12-31 | $4.71M | +29.2% |
| Biotricity Inc. (BTCY) | 2026-03-31 | $3.05M | -5.5% |
| Sonoma Pharmaceuticals, Inc. (SNOA) | 2026-03-31 | $12.11M | +37.3% |
| Spectral AI, Inc. (MDAI) | 2025-12-31 | $10.72M | -34.2% |
| Allurion Technologies, Inc. (ALUR) | 2025-12-31 | $5.66M | -46.6% |
| DarioHealth Corp. (DRIO) | 2025-12-31 | $9.69M | -29.6% |
| Baird Medical Investment Holdings Ltd (BDMD) | 2025-12-31 | $3.65M | -16.7% |
Compare VVOS, NEPH, PROF, BTCY side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗